Tumour-derived HMGB1 released as a consequence of focal intra-tumoural hypoxia thus directly contributes to tumour progression and likely represents an attractive therapeutic target for tumour therapy as demonstrated here in the case of melanoma. The gene discussed is HMGB1; the disease is neoplasm.